38136-96-8

Basic information

• Product Name: 6-Chloro-2-(methylthio)-5-nitropyrimidin-4-amine
• Synonyms: 6-Chloro-2-(methylthio)-5-nitropyrimidin-4-amine
• CAS NO: 38136-96-8
• Molecular Formula: C₅H₅ClN₄O₂S
• Molecular Weight: 220.6368
• Mol File: 38136-96-8.mol
• Article Data: 8

Chemical Properties

• Melting Point: 150-154 °C
• Boiling Point: 429.6±40.0 °C(Predicted)
• Appearance: /
• Density: 1.66±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -1.88±0.10(Predicted)
• CAS DataBase Reference: 6-Chloro-2-(methylthio)-5-nitropyrimidin-4-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Chloro-2-(methylthio)-5-nitropyrimidin-4-amine(38136-96-8)
• EPA Substance Registry System: 6-Chloro-2-(methylthio)-5-nitropyrimidin-4-amine(38136-96-8)

Safety Data

• Hazardous Substances Data: 38136-96-8(Hazardous Substances Data)

Usage

General Description

6-Chloro-2-(methylthio)-5-nitropyrimidin-4-amine is a chemical compound with the molecular formula C6H6ClN4O2S. It is a nitro-substituted pyrimidine derivative that has a chlorine atom at the 6th position, a nitro group at the 5th position, and a methylthio group at the 2nd position of the pyrimidine ring. 6-Chloro-2-(methylthio)-5-nitropyrimidin-4-amine has potential applications in pharmaceutical and agrochemical industries, specifically for the synthesis of new drugs and pesticides. It can also be used as a building block in organic synthesis to create more complex molecules. However, it is important to handle this compound with care, as it may pose health and environmental hazards due to its reactivity and toxicity.

Upstream product

• 1979-97-1 2-(methylthio)-5-nitropyrimidine-4,6-diol 
• 1979-98-2 4,6-dihydroxy-2-methylmercaptopyrimidine 
• 1979-96-0 4,6-dichloro-2-(methylthio)-5-nitropyrimidine 
• 127726-91-4 6-amino-2-methylthio-5-nitropyrimidin-4-ol 

Downstream Products

• 1228587-56-1 ethyl 2-((6-amino-2-(methylthio)-5-nitropyrimidin-4-yl)(3-(pyrrolidin-1-ylmethyl)benzyl)amino)acetate 
• 1228587-60-7 methyl 1-((6-amino-2-(methylthio)-5-nitropyrimidin-4-yl)(3-(pyrrolidin-1-ylmethyl)benzyl)amino)cyclopropanecarboxylate 
• 1228588-11-1 ethyl 2-((6-amino-2-(methylthio)-5-nitropyrimidin-4-yl)(3-cyanobenzyl)amino)acetate 
• 1228588-20-2 ethyl-Nβ-[4-amino-2-methylthio-5-nitropyrimidin-6-yl],Nβ-[3′-(pyrrolidin-1″-ylmethyl)-benzyl]-β-alaninoate 
• 1228588-84-8 C₂₃H₃₀N₆O₆S 
• 1434589-63-5 C₁₇H₁₇ClN₄O₆S 
• 1434589-67-9 C₁₇H₁₉N₅O₆S 
• 1434589-71-5 C₁₇H₁₉N₅O₈S 
• 1539303-96-2 C₁₈H₂₁N₅O₆S 
• 1539303-99-5 ethyl (6-chloro-2-(methylthio)-5-nitropyrimidin-4-yl)(3-methoxybenzyl)carbamate 
• 1539304-00-1 C₁₆H₁₉N₅O₅S 
• 1539304-01-2 C₁₆H₁₉N₅O₇S 
• 1539304-14-7 ethyl 3-((tert-butyldimethylsilyl)oxy)benzyl(6-chloro-2-(methylthio)-5-nitropyrimidin-4-yl)carbamate 
• 1539304-15-8 C₂₁H₃₁N₅O₅SSi 

Relevant articles and documents

Potent and Selective Inhibitors of MTH1 Probe Its Role in Cancer Cell Survival

Recent literature has claimed that inhibition of the enzyme MTH1 can eradicate cancer. MTH1 is one of the housekeeping enzymes that are responsible for hydrolyzing damaged nucleotides in cells and thus prevent them from being incorporated into DNA. We have developed orthogonal and chemically distinct tool compounds to those published in the literature to allow us to test the hypothesis that inhibition of MTH1 has wide applicability in the treatment of cancer. Here we present the work that led to the discovery of three structurally different series of MTH1 inhibitors with excellent potency, selectivity, and proven target engagement in cells. None of these compounds elicited the reported cellular phenotype, and additional siRNA and CRISPR experiments further support these observations. Critically, the difference between the responses of our highly selective inhibitors and published tool compounds suggests that the effect reported for the latter may be due to off-target cytotoxic effects. As a result, we conclude that the role of MTH1 in carcinogenesis and utility of its inhibition is yet to be established.

PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS

The present invention relates to purine derivatives of formula (I), processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.

Identification and optimization of pteridinone toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis

Pteridinone-based Toll-like receptor 7 (TLR7) agonists were identified as potent and selective alternatives to the previously reported adenine-based agonists, leading to the discovery of GS-9620. Analogues were optimized for the immunomodulatory activity and selectivity versus other TLRs, based on differential induction of key cytokines including interferon α (IFN-α) and tumor necrosis factor α (TNF-α). In addition, physicochemical properties were adjusted to achieve desirable in vivo pharmacokinetic and pharmacodynamic properties. GS-9620 is currently in clinical evaluation for the treatment of chronic hepatitis B (HBV) infection.